Evaluation of benazepril in cats with heart disease in a prospective, randomized, blinded, placebo‐controlled clinical trial
Résumé
Background:Heart disease is an important cause of morbidity and mortality in cats,but there is limited evidence of the benefit of any medication.
Hypothesis:The angiotensin-converting enzyme inhibitor benazepril would delaythe time to treatment failure in cats with heart disease of various etiologies.
Animals:One hundred fifty-one client-owned cats
.
Methods:Cats with heart disease, confirmed by echocardiography, with or withoutclinical signs of congestive heart failure, were recruited between 2002 and 2005and randomized to benazepril or placebo in a prospective, multicenter, parallel-group, blinded clinical trial. Benazepril (0.5-1.0 mg/kg) or placebo was administeredPO once daily for up to 2 years. The primary endpoint was treatment failure. Ana-lyses were conducted separately for all-cause treatment failure (main analysis) andheart disease-related treatment failure (supportive analysis).
Results:No benefit of benazepril versus placebo was detected for time to all-causetreatment failure (P= .42) or time to treatment failure related to heart disease(P= .21). Hazard ratios (95% confidence interval [CI]) from multivariate analysis forbenazepril compared with placebo were 1.00 (0.57-1.74) for all-cause failure, and0.99 (0.50-1.94) for forward selection and 0.93 (0.48-1.81) for bidirectional selec-tion models for heart disease-related failure. There were no significant differencesbetween groups over time after administration of the test articles in left atriumdiameter, left ventricle wall thickness, quality of life scores, adverse events, orplasma biochemistry or hematology variables.
Conclusions and Clinical Relevance:Benazepril was tolerated well in cats withheart disease, but no evidence of benefit was detected
Origine : Fichiers éditeurs autorisés sur une archive ouverte
Loading...
